Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Other Investing Activities
Investing cash flows not reported separately.
Novartis AGNYSE: NVS
Other Investing Activities · Q2 FY2026 · quarter ended Jun 2026
Other investing activities turns positive
Q2 FY2026 other investing activities was $218.48M, compared with -$226M a year earlier. Trailing-twelve-month other investing activities was -$577.14M.
Context
- Other investing activities amounted to 0.3% of revenue in FY2025, down 4.3 pp from a year earlier.
- Other investing activities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other investing activities holds near $218.48M or moves back toward the trailing-twelve-month quarterly average of -$144.28M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Investing Activities history
USD · from the cash flow
- Latest · FY2025
- 140.72M USD
- Year-over-year change
- +105.9%
| Period | Period end | Other Investing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.72M | +105.9% |
| FY2024 | 2024-12-31 | (2.38B) | -280.6% |
| FY2023 | 2023-12-31 | (624M) | +56.4% |
| FY2022 | 2022-12-31 | (1.43B) | -7.1% |
| FY2021 | 2021-12-31 | (1.34B) | — |
Other Investing Activities vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -76.2% is the 6th highest of 10, against a peer median of -74.1%.
- Other investing activities amounts to 1.0% of revenue for NVS, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 27.71B DKK | +665.4% | +125.7% | 8.4% | |
| LTM Jun 2026 | €13.23B EUR | +1605.4% | +84.9% | 27.1% | |
| LTM Jun 2026 | $8.56B USD | -25282.4% | — | 28.1% | |
| LTM Jun 2026 | $5.56B USD | -2315.9% | — | 8.4% | |
| LTM Jun 2026 | $1.77B USD | +473.4% | -64.8% | 2.8% | |
| LTM Jun 2026 | £1.62B GBP | +221.7% | — | 4.9% | |
| LTM Jun 2026 | $1.35B USD | — | — | 2.7% | |
| LTM Sep 2026 | $697.24M USD | -74.1% | — | 1.1% | |
| LTM Jun 2026 | $577.14M USD | -76.2% | — | 1.0% | |
| LTM Sep 2026 | $553M USD | -77.1% | — | 0.6% | |
| LTM Jun 2026 | $172M USD | -444.0% | — | 0.3% | |
| Peer median (excluding NVS) | — | -74.1% | +84.9% | 3.8% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.91B | 6.05B | 8.57B | 11.94B | 14.06B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| Deferred Income Tax | 1.63B | 1.13B | 551M | 1.7B | (361.84M) |
| Stock-Based Compensation | 700M | 791M | 865M | 1.04B | 0 |
| Change in Working Capital | (73M) | (796M) | (369M) | (706M) | (3.08B) |
| Accounts Receivables | (352M) | (397M) | (1.5B) | (931M) | (1.13B) |
| Inventory | (102M) | (560M) | (546M) | (225M) | 34.17M |
| Accounts Payables | (111M) | (181M) | 479M | (105M) | (274.4M) |
| Other Working Capital | 492M | 342M | 1.2B | 555M | (1.71B) |
| Other Non-Cash Items | (15.68B) | 359M | (3.44B) | (2.43B) | 3.27B |
| Operating Cash Flow | 15.07B | 14.24B | 14.46B | 17.62B | 19.24B |
| Capital Expenditures | (2.56B) | (2.24B) | (2.75B) | (3.81B) | (1.56B) |
| Acquisitions (Net) | 20.46B | (864M) | (3.57B) | (3.83B) | (3.01B) |
| Purchases of Investments | (16.59B) | (34.81B) | (747M) | (3.65B) | (304.55M) |
| Sales of Investments | 2.74B | 39.49B | 11.6B | 3.7B | 2.19B |
| Other Investing Activities | (1.34B) | (1.43B) | (624M) | (2.38B) | 140.72M |
| Investing Cash Flow | 4.21B | 1.47B | 5.6B | (7.51B) | (4.9B) |
| Debt Repayment | (5.67B) | (2.59B) | (1.94B) | 4.39B | 2.72B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 27.14M |
| Common Stock Repurchased | (3.06B) | (10.65B) | (8.72B) | (8.33B) | (9.26B) |
| Dividends Paid | (7.37B) | (7.51B) | (7.26B) | (7.62B) | (7.86B) |
| Other Financing Activities | (169M) | 181M | 3.63B | (177M) | (577.95M) |
| Financing Cash Flow | (16.26B) | (20.56B) | (14.28B) | (11.74B) | (14.94B) |
| Effect of Forex Changes | (266M) | (32M) | 100M | (298M) | 579.07M |
| Net Change in Cash | 2.75B | (4.89B) | 5.88B | (1.93B) | (24M) |
| Free Cash Flow | 12.52B | 12B | 11.71B | 13.81B | 17.69B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.